Outlook Therapeutics, Inc. Research And Development Expense

• Outlook Therapeutics, Inc. showed a decrease of -34.9% in Research And Development Expense from 2024 to 2025.
• This data is from Outlook Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on December 19, 2025.
• XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2015: $10.15 million | Q2 2015: $9.68 million | Q4 2015: $12.73 million | Q1 2016: $4.14 million | Q2 2016: $12.02 million | Q4 2016: $13.23 million | Q1 2017: $4.12 million | Q2 2017: $4.16 million | Q4 2017: $402.4 thousand | Q1 2018: $5.16 million | Q2 2018: $5.80 million | Q4 2018: $6.07 million | Q1 2019: $5.94 million | Q2 2019: $4.34 million | Q4 2019: $5.85 million | Q1 2020: $4.38 million | Q2 2020: $8.49 million | Q4 2020: $11.95 million | Q1 2021: $8.53 million | Q2 2021: $8.55 million | Q4 2021: $9.87 million | Q1 2022: $12.22 million | Q2 2022: $11.25 million | Q4 2022: $9.86 million | Q1 2023: $544.9 thousand | Q2 2023: $11.10 million | Q4 2023: $4.53 million | Q1 2024: $13.51 million | Q2 2024: $11.20 million | Q4 2024: $9.66 million | Q1 2025: $4.41 million | Q2 2025: $7.13 million | Q4 2025: $3.63 million.
• Over the full 11 years of available data (2015 to 2025), Outlook Therapeutics, Inc.'s Research And Development Expense has declined by 30.1%.
• Historical annual values: Fiscal year 2025: $27.18 million | Fiscal year 2024: $41.76 million | Fiscal year 2023: $26.45 million | Fiscal year 2022: $42.33 million | Fiscal year 2021: $38.96 million | Fiscal year 2020: $26.34 million | Fiscal year 2019: $23.81 million | Fiscal year 2018: $18.50 million | Fiscal year 2017: $23.81 million | Fiscal year 2016: $32.76 million | Fiscal year 2015: $38.88 million.
• Data sourced from SEC EDGAR public filings as of August 7, 2026.

Last verified: August 7, 2026